Table SIII. Evidence table. First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), Date of evaluation

Size: px

Start display at page:

Download "Table SIII. Evidence table. First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), Date of evaluation"

Randolph Bell
5 years ago
Views:

1 Table SIII. Evidence table First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), 2009 (n = 39 a ) van Lümig (13), 2010 (n = 30 a ) Warren (14), 2010 (n = 46 a ) Retrosp b Adalimumab 80 mg (W 0) followed by 40 mg once W (from W1) SC or adalimumab 40 mg According to the response the dose interval was increased or decreased. Adalimumab 80 mg (W0) followed by 40 mg EOW (from W1 12) SC. From W12 48, according to the response the dose interval was maintained, increased or decreased. (Adalimumab 40 mg EOW or 40 mg every 10 days or 40 mg once W. Retrosp. Adalimumab 80 mg (W 0) followed by 40 mg increased to 40 mg weekly the first 4 months. Fotiadou (15), 2012 Retrosp. Adalimumab 80 mg (W 0) followed by 40 mg (n = 52 a ) According to the response the dose interval was increased or decreased López-Ferrer (16), 2013 (n = 119 a ) van Lümig (17), 2013 (n = 85 a ) Retrosp. Adalimumab 80 mg (W 0) followed by 40 mg EOW (From W1) SC. Adalimumab 80 mg (W 0) followed by 40 mg According to the response the dose interval was decreased. Monotherapy Date of evaluation Results (mean) W 16 : 38% : 62% : 69% W 72 : 71% combination therapy W 16 : 56% W24 : 50% W48 : 80% W72 : 67% 100 : 70% Comparing with original : 27% : 10% : 61% Comparing with original : 36% : 7% : 77% Comparing with original : 54% : 15% : 30% : 13% : 13% W 16 : 50% : 7% : 0% : 54% : 23% : 15% : 84% : 64% : 36% : 77% : 65% : 42% W 52 : 56% : 48% : 41% W 16 : 90% : 68% : 42% : 95% : 82% : 56% W 52 : 89% : 75% W 72 : 100% : 88% : 75% W 16 : 64% : 49% : 67% : 60% W 52 : 76% : 70% W 104 : 83% : 71% Comparing with original Comparing with original : 65% : 35% : 11% 100: 0% : 69% : 45% : 17% 100: 6%

2 Menting (18), 2014 (n = 90 TE a ) Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC or 40 mg every 10 days or 40 mg once W. Etanercept de Groot (19), 2006 Retrosp. Etanercept 50 mg BIW SC (W0 12). (n = 50 a ) Berends (20), 2007 (n = 45 a ) Barrera (21), 2008 (n = 66) Etanercept 25 mg BIW SC (W0 12). by 25 mg BIW (W12 24). Naive Non-naive 25 mg BIW SC (W0 24). Retrosp. Etanercept 50 mg BIW SC (W0 12) followed by 25 mg BIW (W12 24) or 25 mg BIW (W0 24). Thereafter one of these treatments by losing 50% of the. Three cycles of 24W. : 83% Comparing with original : 57% : 21% 100: 4% W 96 : 94% Comparing with original : 44% : 22% 100: 0% W 132 : 83% Comparing with original : 50% : 0% 100: 0% : 46% : 27% : 8% W 96 W : 0% : 56% : 31% : 11% 100: 6% : 72% : 38% : 15% 100: 4% : 72% : 44% : 22% 100: 0% : 50% : 50% : 0% 100: 0% : 54% : 42.9% W 52 : 43.5% : 26% : 18% W 52 : 8% : 71% : 22.6% : 6.5% : 57.5% : 62.3% : 85.7% : 21.4% : 7.1% : 60% : 54.1% : 82% : 39% W 18 : 88% : 47% : 71% : 50% : 71% : 24% W 18 : 79% : 64% : 79% : 57% Cycle 1 Cycle 1 : 65.5% : 36.1% : 21.3% : 91.3% : 76.1% : 41.3% : 78.1%

3 Driessen (22), 2008 (n = 80 a ) by 25 mg BIW (W12 24). According to the response the dose of 25 mg BIW was temporary increased. Etanercept 25 mg BIW SC (W0 24). temporary increased. Cycle 2 : 72.4% : 31% : 10.3% Cycle 2 : 94.7% : 63.2% : 31.6% : 66.9%% Cycle 3 : 60% : 33.3% : 20% Cycle 3 : 85.7% : 42.9% : 28.6% : 76% : 66% : 20% : 8% : 59% : 68% : 21% : 5% : 60% Gisondi (40), 2008 Retrosp. Etanercept 25 mg BIW SC. : 74.5% (n = 58) Antoniou (23), 2009 (n = 77 a ) Retrosp. by 25 mg BIW (W12 48). : 79% : 53% increased to 50 mg BIW. : 81% : 49% Driessen (24), 2009 (n = 90 a ) Jiménez-Puya (25), 2009 (n = 58) Mazzotta (26), 2009 (n = 234) Warren (27), 2009 (n = 70 a ) by 25 mg BIW (W12 24) or Etanercept 25 mg BIW SC (W0 W24). temporary increased to 50 mg BIW. Retrosp. Etanercept 50 mg BIW SC or 25 mg BIW SC. c by 25 mg BIW (W12 24) Retrosp. Etanercept 25 mg BIW SC. increased to 50 mg BIW. (psoriasis) : 69% : 39% : 18% : 59.7% W 8 : 77.6% : 41.4% : 6.9% W 16 : 86.8% : 66% : 37.7% : 97.5% : 85% : 57.5% W 32 : 100% : 80.8% : 57.7% W 40 : 94.7% : 84.2% : 52.6% 48W : 100% : 92.3% : 69.2% : 85% : 77.9% : 41% : 67.7% : 85.7% : 73.2% : 81% : 64 % : 43% : 66.7% (psoriasis + psoriatic arthritis) : 79.8% : 61.8% : 80.5% : 67% : 35% : 7% : 55%

4 Antoniou (28), 2010 (n = 35 a ) van Lümig (13), 2010 (n = 30 a ) Zaragoza (29), 2010 (n = 43) Antoniou (30), 2011 (n = 118 a ) Esposito (31), 2012 (n = 61) van Lümig (32), 2012 (n = 152 a ) (n = 158 TE) Puig (33), 2012 (n = 444 a ) Retrosp. d by 25 mg BIW (W12 24). Etanercept 50 mg BIW SC or 25 mg BIW SC (W0 12). Thereafter dosage according to physician. Retrosp. c Etanercept 50 mg BIW SC (W0 12) or 25 mg BIW SC (W0 12) followed by 25 mg BIW SC (W12 24). increased or decreased. Retrosp. by 50 mg once W (from ). Retrosp. c Psoriasis patients with psoriatic arthritis: Etanercept 50 mg BIW SC. Patients with only psoriasis: Etanercept 50 mg BIW, followed by 25 mg BIW SC. Etanercept 50 mg BIW SC or 25 mg BIW SC (W0 12). Thereafter dosage according to the physician. Etanercept 50 mg BIW SC (W0 12) or 50 mg once W or 25 mg BIW (W0 12). After 12 W patients reaching a could continue treatment. After 6 months the decision was made to treat patients continuously or intermittently. : 67% : 41% : 6% : 59% : 57% MPhGAD : 60% : 13% : 3.3% : 58% : 19% : 3.3% : 79% : 25% : 81.4% : 60.5% : 73.8% : 90.5% : 71.4% : 79.6% W 72 : 81.3% W 96 : 38.2% 0 : 87.6% W 144 : 88.4% : 59% : 25% : 81% : 47% : 82% : 54% W 72 : 87% : 52% : 82% : 54.1% : 73.3% : 90.2% : 78.7% : 85.9% W 52 : 90.2% : 83.6% : 87.9% W 104 : 91.8% : 86.9% : 88.4% W 156 : 91.8% : 83.6% : 86.9% : 65.6% : 23.6% : 5.1% : 69.7% : 38.1% : 14.9% : 36.6% W 108 : 40.8% W 156 : 50% W 204 : 59.4% W 264 : 60% Overall Continuous regimen Intermittent regimen : 88.4% : 63.9% : 37.8% : 69.6% : 66.4% MPhGAD: 62.5% : 63% : 34.8% : 64% : 38.4%

5 Chiu (34), 2013 (n = 59 a ) van Lümig (35), 2013 (n = 131 a ) (n = 134 TE) Menting (18), 2014 (n = 178 TE a ) Infliximab Kalb (41), 2005 (n = 52 a ) Gisondi (40), 2008 (n = 40) Gisondi (36), 2013 (n = 83) Menting (18), 2014 (n = 40 TE a ) Retrosp. Etanercept 25 mg BIW SC (W0 24). increased to 50 mg BIW SC (for 4 12W). Thereafter dose was reduced to 25 mg BIW SC. Etanercept mean weakly dose 64.1 mg ± 14.0 mg. Etanercept initiated by 50 mg BIW SC (W0 12) or 50 mg once W or 25 mg BIW. Thereafter, 50 mg BIW or dose frequency reduction (every 5, 7 or 10 days). Naive Non-naive : 91.3% : 76.1% : 50.8% : 81.4% : 79.6% MPhGADR: 65.6% : 66.3% Continuous regimen : 39.3% : 79% Intermittent regimen : 54.3% W 36 : 73.9 : 52.6% : 32.1% : 63.4% : 66.7% MPhGAD: 46.9% W 36 : 68.8% Continuous regimen : 41.9% W 36 : 46.7% Intermittent regimen : 28.6% : 83.1% : 65.6% : 39.6% : 74.6% : 75.7% MPhGAD: 59.4% Continuous regimen Intermittent regimen : 69.2% : 47.3% PhGA 0 1: 73.4% : 64.3% : 36.6% PhGA 0 1: 61.8% : 48% : 26% : 3% : 47% : 59% : 37% : 14% : 61% : 67.9% : 38.1% : 14.9% : 36.6% W 108 : 40.8% W 156 : 50% W 204 : 59.4% W 264 : 60% : 32% : 9.9% W 52 : 13.3% : 12% : 4% W 52 : 13% Retrosp. Infliximab 5 mg/kg IV. PhGA 0 W 14 PhGA 0: 38.5% W 0, 2, 6 and every 8 W. PhGA 1 PhGA 1: 50% Retrosp. Infliximab 5 mg/kg W 0, 2, 6 and every 8 W. : 88.8% Infliximab 5 mg/kg W 0, 2, 6 and every 8 W. Infliximab ± 5 mg/kg W 0, 2, 6 and every 8 W. Naive W 4 : 32% PR: 64% W 28 : 96% : 69% : 85% : 53% : 35.3% W 52 : 18.2%

6 Ustekinumab Clemmensen (37), 2011 (n = 71) Laws (38), 2012 (n = 129 a ) Ruiz Salas (39), 2012 (n = 36 a ) Gisondi (36), 2013 (n = 79) Acitretin Piaserico (42), 2014 (n = 62) Fumarates Carboni (43), 2004 (n = 40) Inzinger (44), 2013 (n = 272) Non-naive : 38% : 12% W 52 : 14% W 16 : 80% Ustekinumab 45 or 90 mg (W 0, 4, and every 12 W). e Retrosp. Ustekinumab 45 or 90 mg (W 0, 4 and every W 16 : 82.7% 12 W. e : 63% : 29.1% : 66.7% : 65.5% Retrosp. Ustekinumab 45 mg (W 0, 4 and every 8 12 W). e Ustekinumab 90 mg (W 0, 4 and every 8 12 W). Ustekinumab both groups [45 and 90 mg] (W 0, 4 and every 8 12 W). Ustekinumab 45 or 90 mg (W 0, 4 and every 12 W). Dosing is weight dependent. Individuals weight ( 100 kg= ustekinumab 45mg; > 100kg= 90 mg). : 89.6% : 79.3% : 65.5% PR: 80.7% : 89.6% : 79.3% : 75.9% : 80.9% W 36 : 89.6% : 89.6% : 75.9% : 89.3% : 85.7% : 57.1% : 28.5% : 75.6% : 57.1% : 28.5% : 14.2% : 48.2% W 36 : 85.7% : 71.4% : 54.1% : 80% : 91.7% : 75% : 58.3% : 79.5% : 83.3% : 69.4% : 63.9% : 71.9% W 36 : 88.8% : 71.4% : 57.1% : 86.8% W 4 : 28% : 82% W 28 : 82% : 58% : 60% Retrosp. Acitretin mean 0.38 mg/kg/day. : 27% Fumarates mg/day. By remission doses were gradually reduced. Retrosp. Fumarates mg/day. W 4 : 39.6% : 63% : 80% 100 : 76% : 47% : 9% 100: 1% : 82% : 63% : 27% 100: 5%

7 : 90% : 76% : 34% 100: 12% Cyclosporine Piaserico 42), 2014 Retrosp. Cyclosporine mean 3.5 mg/kg/day. : 46% (n = 36) Methotrexate Gisondi (40), 2008 Retrosp. Methotrexate 15 mg/week IM. : 47.6% (n = 43) Inzinger (44), 2013 (n = 72) Piaserico (42), 2014 (n = 74) Retrosp. Methotrexate 10 mg/week SC increased to 20 mg/week SC. 100 W12 : 67% : 40% : 12% 100: 10% : 76% : 62% : 28% 100: 10% : 87.5% : 81% : 44% 100: 19% Retrosp. Methotrexate mean 11.7 mg/week. : 49% a Additional conventional systemic therapies. b Patient switched from etanercept. c Patients with psoriasis with or without psoriatic arthritis. d Patients switching from efalizumab. e Dosing is weight dependent. Individuals weight ( 100 kg= ustekinumab 45 mg; >100 kg= 90 mg). Retrosp.: retrospective; : prospective; BIW: biweekly; BSA: body surface area; : mean BSA decrease; EOW: every other week; IM: intramuscular; IV: intravenous; : Psoriasis Area and Severity Index; : mean decrease; PhGA: Physician Global Assessment; MPhGAD: mean PhGA decrease; SC: subcutaneous; TE: treatment episode.

This questionnaire was used both during the face-to-face interviews with the

Additional file 1: Primary research questionnaire This questionnaire was used both during the face-to-face interviews with the dermatologists and during the expert panel 1. During the last month, how many